Today, the White House released a statement proposing new action to lower health care and prescription drug costs. Among these proposals, is a new framework that would allow the federal government additional leeway in granting compulsory licenses to other drug manufacturers when the cost of taxpayer-funded and patented drugs is deemed to restrict access to the drug. The Federal Government has long had the ability to compel licenses to taxpayer-funded and patented drugs under the Bayh-Dole Act of 1980, if the drug was developed with government funds and is “not accessible to the public.” Historically, the accessibility of a drug was determined by the patent owner’s ability to supply the drug in sufficient quantities. The proposed new rule, promulgated under the Department of Commerce and Health and Human Services, would also allow the government to consider the price of a drug in determining whether it is “accessible to the public.” The proposed rule is currently open for notice and comment by the public.